{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:41:03Z","timestamp":1788414063388,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00198-020-05517-7","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T16:39:50Z","timestamp":1593621590000},"page":"1817-1828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures"],"prefix":"10.1007","volume":"31","author":[{"given":"J. A.","family":"Kanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gudnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Siggeirsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lorentzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vandenput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"5517_CR1","unstructured":"Kanis JA on behalf of the World Health Organization Scientific Group (2008a) Assessment of osteoporosis at the primary health-care level. Technical report. WHO Collaborating Centre, University of Sheffield, UK. Available at http:\/\/www.shef.ac.uk\/FRAX\/index.htm. Accessed 25 March 2020"},{"key":"5517_CR2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008b) FRAX\u2122 and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397","journal-title":"Osteoporos Int"},{"key":"5517_CR3","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Od\u00e9n A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C, on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239\u20132256","journal-title":"Osteoporos Int"},{"key":"5517_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11657-013-0166-8","volume":"9","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV, the Epidemiology and Quality of Life Working Group of IOF (2014) Worldwide uptake of FRAX. Arch Osteoporos 9:166. https:\/\/doi.org\/10.1007\/s11657-013-0166-8","journal-title":"Arch Osteoporos"},{"key":"5517_CR5","volume-title":"CG146: osteoporosis: fragility fracture risk. Short clinical guideline- evidence and recommendation","author":"National Institute for Health and Care Excellence","year":"2012","unstructured":"National Institute for Health and Care Excellence (2012) CG146: osteoporosis: fragility fracture risk. Short clinical guideline- evidence and recommendation. National Clinical Guideline Centre, London"},{"key":"5517_CR6","unstructured":"National Institute for Health and Care Excellence (2017) TA 464: bisphosphonates for treating osteoporosis. Technology appraisal guidance 464. National Institute for Health and Care Excellence, London nice.org.uk\/guidance\/ta464. Accessed 25 March 2020"},{"key":"5517_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"5517_CR8","volume-title":"Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2006","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. CHMP, London"},{"key":"5517_CR9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721\u2013739","journal-title":"J Bone Miner Res"},{"key":"5517_CR10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1359\/jbmr.040917","volume":"19","author":"P Haentjens","year":"2004","unstructured":"Haentjens P, Johnell O, Kanis JA, Bouillon R, Cooper C, Lamraski G, Vanderschuren D, Kauffman J-M, Boonen S (2004) Gender-related differences in short and long-term absolute risk of hip fracture after Colles\u2019 or spine fracture: Colles\u2019 fracture as an early and sensitive marker of skeletal fragility in men. J Bone Miner Res 19:1933\u20131944","journal-title":"J Bone Miner Res"},{"key":"5517_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00198-003-1514-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Pettersen C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175\u2013179","journal-title":"Osteoporos Int"},{"key":"5517_CR12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ III, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375\u2013382","journal-title":"Bone"},{"key":"5517_CR13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00198-014-2875-2","volume":"26","author":"L Hansen","year":"2015","unstructured":"Hansen L, Petersen KD, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Jensen JE, Harslof T, Vestergaard P (2015) Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. Osteoporos Int 26:513\u2013519","journal-title":"Osteoporos Int"},{"key":"5517_CR14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s001980170131","volume":"12","author":"O Johnell","year":"2001","unstructured":"Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207\u2013214","journal-title":"Osteoporos Int"},{"key":"5517_CR15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jbmr.35","volume":"25","author":"LM Giangregorio","year":"2010","unstructured":"Giangregorio LM, Leslie WD (2010) Manitoba bone density program. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400\u20131405","journal-title":"J Bone Miner Res"},{"key":"5517_CR16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s002239900446","volume":"62","author":"KE Dretakis","year":"1998","unstructured":"Dretakis KE, Dretakis EK, Papakitsou EF, Psarakis S, Steriopoulos K (1998) Possible predisposing factors for the second hip fracture. Calcif Tissue Int 62:366\u2013369","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"5517_CR17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-006-0125-y","volume":"17","author":"T Nymark","year":"2006","unstructured":"Nymark T, Lauritsen JM, Ovesen O, R\u00f6ck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17(9):1353\u20131357","journal-title":"Osteoporos Int"},{"key":"5517_CR18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320\u2013323","journal-title":"JAMA"},{"key":"5517_CR19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1359\/jbmr.090207","volume":"24","author":"J Ryg","year":"2009","unstructured":"Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res 24:1299\u20131307","journal-title":"J Bone Miner Res"},{"key":"5517_CR20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2008.092775","volume":"68","author":"TACM van Geel","year":"2016","unstructured":"van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J (2016) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99\u2013102","journal-title":"Ann Rheum Dis"},{"key":"5517_CR21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780","journal-title":"Osteoporos Int"},{"key":"5517_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruy\u00e8re O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J-Y (2020) Algorithm for the management of patients at low\/middle\/high risk of osteoporotic fracture: a global perspective. Osteoporos Int 31:1\u201312","journal-title":"Osteoporos Int"},{"key":"5517_CR23","unstructured":"Bjornsson G, Bjornsson OJ, Davidsson D et al (1982) Report abc XXIV. Health survey in the Reykjavik Area. \u2013 Women. Stages I-III, 1968\u20131969, 1971\u20131972 and 1976-1978. Participants, invitation, response etc. The Icelandic Heart Association, Reykjav\u00edk"},{"key":"5517_CR24","unstructured":"Bjornsson OJ, Davidsson. D., Olafsson H et al (1979) Report XVIII. Health Survey in the Reykjavik Area. \u2014 Men. Stages I\u2013III, 1967\u20131968, 1970\u20131971 and 1974\u20131975. Participants, invitation, response etc. The Icelandic Heart Association, Reykjav\u00edk"},{"key":"5517_CR25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"5517_CR26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10654-007-9163-9","volume":"22","author":"K Siggeirsdottir","year":"2007","unstructured":"Siggeirsdottir K, Aspelund T, Sigurdsson G, Mogensen B, Chang M, Jonsdottir B, Eiriksdottir G, Launer LJ, Harris TB, Jonsson BY, Gudnason V (2007) Inaccuracy in self-report of fractures may underestimate association with health outcomes when compared with medical record based fracture registry. Eur J Epidemiol 22:631\u2013639","journal-title":"Eur J Epidemiol"},{"key":"5517_CR27","first-page":"131","volume-title":"Statistical methods in cancer research","author":"NE Breslow","year":"1987","unstructured":"Breslow NE, Day NE (1987) Statistical methods in cancer research, vol 2. IARC scientific publications, no 32, Lyon, pp 131\u2013135"},{"key":"5517_CR28","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2015-3951","volume":"101","author":"K Albertsson-Wikland","year":"2016","unstructured":"Albertsson-Wikland K, Martensson A, Savendahl L, Niklasson A, Bang P, Dahlgren J, Gustafsson J, Kristr\u00f6m B, Norgren S, Pehrsson NG, Od\u00e9n A (2016) Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab 101:2149\u20132159","journal-title":"J Clin Endocrinol Metab"},{"key":"5517_CR29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, de Laet C, Jonsson B (2000) Long-term risk of osteoporotic fractures in Malmo. Osteoporisis Int 11:669\u2013674","journal-title":"Osteoporisis Int"},{"key":"5517_CR30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1359\/jbmr.2002.17.7.1237","volume":"17","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Mineral Res 17:1237\u20131244","journal-title":"J Bone Mineral Res"},{"key":"5517_CR31","unstructured":"United Nations (2019) Department of Economic and Social Affairs. World Population Prospects 2019 https:\/\/populationunorg\/wpp\/Download\/Standard\/Population\/ accessed 15 Feb 2020"},{"key":"5517_CR32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00198-009-0845-x","volume":"20","author":"H Johansson","year":"2009","unstructured":"Johansson H, Kanis JA, Ode\u2019n A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675\u20131682","journal-title":"Osteoporos Int"},{"key":"5517_CR33","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033\u20131046","journal-title":"Osteoporos Int"},{"key":"5517_CR34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.plefa.2012.04.010","volume":"87","author":"A Sekikawa","year":"2012","unstructured":"Sekikawa A, Steingrimsdottir L, Ueshima H, Shin C, Curb JD, Evans RW, Hauksdottir AM, Kadota A, Choo J, Masaki K, Thorsson B, Launer LJ, Garcia ME, Maegawa H, Willcox BJ, Eiriksdottir G, Fujiyoshi A, Miura K, Harris TB, Kuller LH, Gudnason V (2012) Serum levels of marine-derived n-3 fatty acids in Icelanders, Japanese, Koreans, and Americans--a descriptive epidemiologic study. Prostaglandins Leukot Essent Fatty Acids 87:11\u201316","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"5517_CR35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00774-012-0371-3","volume":"30","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Johansson H, Od\u00e9n A, McCloskey EV (2012b) The distribution of FRAX\u00ae based probabilities in women from Japan. J Bone Miner Metab 30:700\u2013705","journal-title":"J Bone Miner Metab"},{"key":"5517_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-009-1034-7","volume":"21","author":"B Dawson-Hughes","year":"2010","unstructured":"Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ III (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21:41\u201352","journal-title":"Osteoporos Int"},{"key":"5517_CR37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00198-011-1864-y","volume":"23","author":"H Johansson","year":"2012","unstructured":"Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907\u2013915","journal-title":"Osteoporos Int"},{"issue":"11","key":"5517_CR38","doi-asserted-by":"publisher","first-page":"e0206047","DOI":"10.1371\/journal.pone.0206047","volume":"13","author":"M Thordardottir","year":"2018","unstructured":"Thordardottir M, Lindqvist EK, Lund SH et al (2018) Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS One 13(11):e0206047. https:\/\/doi.org\/10.1371\/journal.pone.0206047","journal-title":"PLoS One"},{"key":"5517_CR39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473","journal-title":"Bone"},{"key":"5517_CR40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fractures. Osteoporos Int 15:108\u2013112","journal-title":"Osteoporos Int"},{"key":"5517_CR41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Pettersen C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342","journal-title":"Osteoporos Int"},{"issue":"1","key":"5517_CR42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Od\u00e9n A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX. Arch Osteoporos 11(1):25","journal-title":"Arch Osteoporos"},{"key":"5517_CR43","unstructured":"Chakhtoura M, Baddoura R , El-Hajj Fuleihan G (2013) Lebanese FRAX-based osteoporosis guidelines. http:\/\/www.osteos.org.lb\/admin\/uploads\/Full%20document.pdf accessed 19 Oct 2015"},{"key":"5517_CR44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439\u20131443","journal-title":"Osteoporos Int"},{"key":"5517_CR45","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381","journal-title":"Osteoporos Int"},{"key":"5517_CR46","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864\u20131873","journal-title":"CMAJ"},{"key":"5517_CR47","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) (2015) Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015 (SIGN publication no 142)[March 2015] Available from URL: http:\/\/wwwsignacuk accessed 11 May 2015"},{"key":"5517_CR48","unstructured":"Agency for care effectiveness (2018) Osteoporosis \u2013 identification and management in primary care. Available at http:\/\/wwwace-htagovsg\/our-guidance\/osteoporosis-identification-and-management-in-primary-carehtml Accessed 22 Dec 2019"},{"key":"5517_CR49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198\u2013202","journal-title":"J Bone Miner Res"},{"key":"5517_CR50","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"5517_CR51","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, M\u00f6ricke R, L\u00f3pez-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240","journal-title":"Lancet"},{"key":"5517_CR52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00198-019-05142-z","volume":"31","author":"CM Parsons","year":"2020","unstructured":"Parsons CM, Harvey N, Shepstone L, Kanis JA, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I, Holland R, Redmond NM, Howe A, Marshall T, Peters TJ, Torgerson D, O'Neill TW, McCloskey E, Cooper C, SCOOP Trial Group (2020) Systematic screening using FRAX leads to increased use of, and adherence to, anti-osteoporosis medications: the Uk SCOOP Trial. Osteoporosis Int 2018 31:67\u201375","journal-title":"Osteoporosis Int 2018"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05517-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05517-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05517-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T02:02:21Z","timestamp":1625104941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05517-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["5517"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05517-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the National Bioethics Committee and the Data Protection Authority in Iceland. All participants gave informed written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"V Gudnason, G Sigurdsson, K Siggeirsdottir, E Liu, L Vandenput and H Johansson have no competing interests to declare.N. Harvey has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma.EV McCloskey has received consultancy\/lecture fees\/grant funding\/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, SanofiAventis, Servier, Synexus, UCB, Viiv, Warner Chilcott, I3 Innovus and Unilever.JA Kanis reports grants from Amgen, Eli Lilly and Radius Health and consulting fees from Theramex. JAK is the architect of FRAX\u00ae but has no financial interest.M Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, all outside the presented work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}